Shares of Eleven Biotherapeutics (Nasdaq: EBIO) rose 5.8% in regular trading and a further 2.1% to $1.48 after hours, after the company announced positive progress with its bladder cancer drug candidate, Vicinium, a recombinant fusion protein designed to specifically target and deliver an anti-cancer payload directly to tumor cells.
It said that its Phase III registration trial of Vicinium in non-muscle invasive bladder cancer (NMIBC) has exceeded 50% enrollment and that the independent Data and Safety Monitoring Board (DSMB) for the trial has recommended that the trial continue as planned. The DSMB reviewed available data to assess the risk/benefit to patients on drug and recommended that the trial continue without modification.
Eleven took over the development of Vicinium along with its $13.5 million acquisition of Canada’s Viventia Bio last September.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze